Patents by Inventor Jere PIKKARAINEN

Jere PIKKARAINEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy For Cancer
    Publication number: 20170348345
    Abstract: A method of treating brain cancer in an immune-competent human patient by administering ternozolornide to the immune-competent human patient, the improvement comprising administering to said immune-competent human patient a viral vector.
    Type: Application
    Filed: July 10, 2017
    Publication date: December 7, 2017
    Inventors: Haritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA
  • Combination Therapy for Cancer
    Publication number: 20130331442
    Abstract: An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: FINVECTOR VISION THERAPIES LTD
    Inventors: Haritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA
  • Combination Therapy for Cancer
    Publication number: 20130310444
    Abstract: An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning the another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
    Type: Application
    Filed: January 18, 2012
    Publication date: November 21, 2013
    Applicant: Ark Therapeutics, Ltd.
    Inventors: Haritha Samaranayake, Jere Pikkarainen, Ann-Marie Maatta, Seppo Yla-Herttuala
  • Combination Therapy for Cancer
    Publication number: 20130296407
    Abstract: An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
    Type: Application
    Filed: May 1, 2013
    Publication date: November 7, 2013
    Applicant: ARK THERAPEUTICS, LTD.
    Inventors: Haritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA